Regeneron Pharmaceuticals (MIL:1REGN) Other Income (Expense) : €434 Mil (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Regeneron Pharmaceuticals Other Income (Expense)?

Regeneron Pharmaceuticals's other income expense for the Regeneron Pharmaceuticals's pretax income for the three months ended in Mar. 2025 was €137 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2025 was €434 Mil.

Regeneron Pharmaceuticals Other Income (Expense) Historical Data

The historical data trend for Regeneron Pharmaceuticals's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Other Income (Expense) Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Income (Expense)

Get a 7-Day Free Trial

238.96

345.59

18.12

-248.23

127.02

Regeneron Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Income (Expense)	Get a 7-Day Free Trial															-180.41	365.93	126.05	-195.49	137.36

Regeneron Pharmaceuticals Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €434 Mil.

Regeneron Pharmaceuticals (MIL:1REGN) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIL:1REGN) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 0R2M:UK RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines